{"id":413929,"date":"2019-07-25T18:02:01","date_gmt":"2019-07-25T18:02:01","guid":{"rendered":"http:\/\/www.abnewswire.com\/pressreleases\/?p=413929"},"modified":"2019-07-25T18:02:01","modified_gmt":"2019-07-25T18:02:01","slug":"2019-us-pharmaceutical-drugs-market-and-global-forecast-to-2022","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/2019-us-pharmaceutical-drugs-market-and-global-forecast-to-2022_413929.html","title":{"rendered":"2019 US Pharmaceutical Drugs Market And Global Forecast To 2022"},"content":{"rendered":"
\"2019<\/a><\/p>\n
\n
Novartis AG Was The Largest Company In Pharmaceutical Drugs Market, Global Opportunities And Strategies, Says TBRC\u2019s Report (Companies: Novartis AG, Sanofi S.A, Pfizer Inc. And Gilead Sciences, Inc)\n<\/div>\n<\/div>\n<\/div>\n
TheBusinessResearchCompany.com offers Pharmaceutical Drugs Market By Segments (Musculoskeletal Disorders Drugs, Cardiovascular Drugs, Oncology Drugs, Anti-Infective Drugs, Metabolic Disorder Drugs, Central Nervous System Drugs, Genito-Urinary Drugs, Respiratory Diseases Drugs, Gastrointestinal Drugs, Hematology Drugs, Dermatology Drugs, Ophthalmology Drugs) – Global Forecast To 2022″ from its store.\n<\/div>\n

The global pharmaceutical drug market was worth $934.8 billion in 2017 and has grown at a CAGR of 5.16% during 2013-2017. The market is expected to grow at a CAGR of 5.78% during 2017-2021 and is forecast to be worth $1,170.4 billion by 2021. Aging populations, income growth especially in emerging economies and the high prices of new drugs are factors leading to steadily increasing per capita drugs expenditure. View Complete report @ https:\/\/www.thebusinessresearchcompany.com\/report\/pharmaceutical-drugs-market<\/a><\/strong><\/p>\n

High Costs of Drug Approval – Drug approval involves series of research stages and regulatory approvals that are often expensive. Drug approval process include about four phases of clinical trials and various stages of screening process with the regulatory body such as FDA. The costs of failed clinical trials is also high as clinical trial phases involves huge investments. According to Tufts Center for the Study of Drug Development, the cost of bringing a new drug from its conception to shelves is about $2.7 billion in 2017. This cost has increased more than 10 folds, with the cost of bringing a new drug to the market being $320 million in 1990s.  thus indicating high drug approval costs, which affected the growth of the pharmaceutical drugs market.<\/p>\n

The Pharmaceutical drugs market is segmented by specialty, and by geography. <\/strong><\/p>\n

By Specialty – The pharmaceutical drugs market is segmented by specialty into<\/strong><\/p>\n

    \n